Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. - Wikidata - wikimedia - TriplyDB

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

http://www.wikidata.org/entity/Q34226107

about

Neo-adjuvant chemotherapy for invasive bladder cancer Mechanisms of Progranulin Action and Regulation in Genitourinary Cancers Role of copper transporters in platinum resistance Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer Muscle-invasive urothelial bladder cancer: an update on systemic therapy Optimal management of muscle-invasive bladder cancer - a review Bladder cancer in 2011: the dawn of personalized medicine Role of systemic chemotherapy in urothelial urinary bladder cancer Multimodal management of muscle-invasive bladder cancer Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery Outcome of urinary bladder cancer after combined therapies Bladder cancer in the elderly patient: challenges and solutions Radical transurethral resection alone, robotic or partial cystectomy, or extended lymphadenectomy: can we select patients with muscle invasion for less or more surgery?Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma Downstaging to non-invasive urothelial carcinoma is associated with improved outcome following radical cystectomy for patients with cT2 disease Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.Systemic therapy for bladder cancer finally comes into a new age.A place for precision medicine in bladder cancer: targeting the FGFRs.Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.Bladder cancer: narrowing the gap between evidence and practice Refining patient selection for neoadjuvant chemotherapy before radical cystectomy A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment.Genoproteomic mining of urothelial cancer suggests {gamma}-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapy.Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat.Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors.Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.Targeted androgen pathway suppression in localized prostate cancer: a pilot study.The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial.Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data.A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy.Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer.

P2860

Q24247506-D841693D-CB24-4458-BF59-08648D2B4FEA Q26741917-27A9393A-39CD-44D9-B514-140F904849EA Q26767028-9C741966-7243-4D32-86B9-0F7A385816E2 Q26773664-FA7FA2B4-3A45-46F8-B0B5-DAC4C9E79FA5 Q26775780-1D7C4FC5-39ED-418B-A485-9275DBB4F089 Q26784038-E811B44F-5C35-4257-BDFE-7212BA28F04D Q26998718-523C70DF-C831-486C-B6E6-E52890D1B04F Q27010323-CB7B37BD-C07A-4960-9C34-58DD1CD57C54 Q27011624-D7E9B0C8-C1B5-4927-8A9A-1F9EAB2652F9 Q27024948-772B2CFA-A73E-434C-B782-1F5E90E59BFB Q27026717-4411F851-44A3-4A58-BD76-F5574DC56ABE Q28066214-08C8F225-14CF-4424-8C89-062740D09674 Q28072814-B4659EE7-39C3-4E80-BF36-CDD9A559A324 Q28074930-E66D6EAD-122E-4CA4-A81D-810F4F08D3E1 Q28076180-381B4863-32D6-4D6F-8F06-2929CF3B25E0 Q28082782-139851BB-AD47-4757-B6F2-FCF41027395B Q28084159-06E6EE73-63EA-445B-B21F-8AFD21F76F03 Q28084715-2A32BE6F-6307-452A-B55B-559BD8E19F44 Q28262766-D7C5C600-50B9-478D-A681-2E9BDAF1C7F7 Q28278664-96959251-0B5D-4AEE-8706-3205B81B72DF Q28552143-FEDA5325-8B36-4A36-AD16-E09F8A56CB63 Q28552735-3EA62D79-1A7C-46CB-B255-628A83DCD005 Q30240816-5DF7A621-A44B-428D-9179-2329DCA9EBC4 Q30249047-B5C85BE9-9FE7-47CD-A258-7DB2095AB067 Q30249143-B96BC619-97EF-4E81-AF27-688569046F84 Q30277868-4801B127-168A-4C96-8279-F84550D5B8E9 Q30362052-64D69EF8-0FA2-4F75-9EA7-03034CAA3229 Q30408866-7C3443BF-7835-49AE-BFB2-E6BD0CBDF4F0 Q30421675-346F457C-7529-4C29-A594-1E839D28479E Q30434237-8DEB10AA-A7DE-4F66-BAF2-61A8E3A5FC9D Q30437629-6834CF0E-1002-4E85-8A0E-E0BF943B37D3 Q30459452-F6556196-CD47-4CC1-8E4E-F441395EF3B8 Q30485127-8B216EB8-AD0B-4D03-954D-59DDF9D58943 Q30538788-104F6553-A204-4E5B-AF85-7B5AAADCDB1D Q30563985-6EEEA39E-9CFF-4278-9B69-FB86B5C0DBFA Q30845020-9252F5F4-7F09-48CE-B738-6D633271E9AD Q30870825-9B5732FD-FBE0-4825-A28D-F41E7EB24C8C Q30976026-84984C38-B73B-471C-A2EB-3F4D6733B7C3 Q30981992-97CE73B5-BC81-4984-A9C6-FAFFF3EB8992 Q33360846-6BDDE1A1-2CD4-4D81-8FB6-62986FA1C555

P2860

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

http://www.wikidata.org/entity/Q34226107

description

2003 nî lūn-bûn

@nan

2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Neoadjuvant chemotherapy plus ...... cally advanced bladder cancer.

@ast

Neoadjuvant chemotherapy plus ...... cally advanced bladder cancer.

@en

Neoadjuvant chemotherapy plus ...... cally advanced bladder cancer.

@nl

type

label

Neoadjuvant chemotherapy plus ...... cally advanced bladder cancer.

@ast

Neoadjuvant chemotherapy plus ...... cally advanced bladder cancer.

@en

Neoadjuvant chemotherapy plus ...... cally advanced bladder cancer.

@nl

prefLabel

Neoadjuvant chemotherapy plus ...... cally advanced bladder cancer.

@ast

Neoadjuvant chemotherapy plus ...... cally advanced bladder cancer.

@en

Neoadjuvant chemotherapy plus ...... cally advanced bladder cancer.

@nl

P1433

Q34226107-896F6F7F-7533-455C-8038-C23FE9A9A17C

P1476

Q34226107-6EE8DC7B-6FF5-45E3-A24A-33FFB77BD043

P2093

Q34226107-07860C21-E821-41A1-B1D9-FBFBA04CA99E

Q34226107-0C28FD3A-BD7A-4297-8D02-9E146ABB5EBD

Q34226107-0FB0F904-E074-4A72-9E97-B912F161E200

Q34226107-27E24F81-68FD-4178-96FE-8C33E697B0D2

Q34226107-35B20661-4815-4E06-9154-E57D1565D9A0

Q34226107-A1F834D2-5E69-4AEC-96F4-8D335AFB7F49

Q34226107-A54B3DC0-7C8C-42B2-A530-DD7942D1590A

Q34226107-BDA2A0CD-48D8-446F-992D-4DDDB824C2A8

Q34226107-C4C1D24F-BCB2-4620-A24B-4C9204D198D6

Q34226107-CFE1B4BF-E57C-48E4-AF89-E45F2E71D5A2

P304

Q34226107-DC86404F-759B-402C-A14F-BCEC50866E22

P31

Q34226107-9A470A67-769E-4959-8B82-E0E5ED2A48CD

P356

Q34226107-BE63F53A-7271-44DD-A095-D5E071398983

P407

Q34226107-4652AEDB-7258-41D6-9FDE-3F6B868737C5

P433

Q34226107-E34EEF4C-2E1E-4418-AFE4-90E79F301310

P478

Q34226107-6ADE910F-4049-4085-9180-1DCC1050358B

P577

Q34226107-35A13799-F940-4D15-AF21-597D5CAEDCD0

P698

Q34226107-BF214C22-C73A-467D-A0ED-9884AB055ED1

P921

Q34226107-82909738-C372-4DD8-A83E-7F123F8B4E2D

P356

P1433

The New England Journal of Medicine

P1476

Neoadjuvant chemotherapy plus ...... cally advanced bladder cancer.

@en

P2093

Catherine M Tangen

http://www.w3.org/2001/XMLSchema#string

David P Wood

http://www.w3.org/2001/XMLSchema#string

Derek Raghavan

http://www.w3.org/2001/XMLSchema#string

Donald L Trump

http://www.w3.org/2001/XMLSchema#string

E David Crawford

http://www.w3.org/2001/XMLSchema#string

H Barton Grossman

http://www.w3.org/2001/XMLSchema#string

Michael F Sarosdy

http://www.w3.org/2001/XMLSchema#string

Nicholas J Vogelzang

http://www.w3.org/2001/XMLSchema#string

Ralph W deVere White

http://www.w3.org/2001/XMLSchema#string

Ronald B Natale

http://www.w3.org/2001/XMLSchema#string

P304

859-866

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA022148

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

349

http://www.w3.org/2001/XMLSchema#string

P577

2003-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12944571

http://www.w3.org/2001/XMLSchema#string

P921